Astrazeneca Ab

Acesion Pharma Aps

Pulmagen Therapeutics (Synergy) Limited

Jaguahr Therapeutics Pte Ltd

Antonio Mete

David R Cheshire

Stephen Connolly

Iain Walters

Barry John Teobald

Rhonan Lee Ford

Ulrik Svane Sørensen

David Cox

Andrew Mather

Austen Pimm

Peter Richard Hamley

Ian Millichip

Richard James Bull

Deborah Chen

Tim Birkinshaw

Mark Graham

John King-underwood

Philip Vellacott Thorne

Ulrik Sørensen

Ulrik Svane SØRENSEN

The present disclosure relates to compounds of formula (I), which are suitable as AhR modulators, in particular AhR inhibitors. The disclosure also relates to compositions comprising said compounds and use of said compounds or compositions in treatment, in particular in the treatment of cancer. The disclosure further relates to methods of preparing said compounds.

Tetrahydropyridopyrimidine derivatives as AhR modulators

A compound of the general formula (I), and the pharmaceutical composition including a compound of formula (I) and optionally a pharmaceutically acceptable additive. Also, the treatment of a cardiac disease, disorder or condition in a mammal, which includes the administration to the mammal a therapeutically effective amount of at least one compound of formula (I), or the pharmaceutically acceptable salt thereof.

Potassium channel inhibitors

The present invention relates to a compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.

A compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.

The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed. 

Quinuclidine derivatives as muscarinic M3 receptor antagonists

The invention provides compounds of formula (I) wherein Ris a group of formula (II) or (IIIa) or (IIIb) and R, R, R, R, a, b and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation (I), (II), (IIIa), (IIIb). 

Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists

The present invention provides compounds of formula (I) in which y, m, n, R, Rand Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Substituted 1-cyanoethylheterocyclylcarboxamide compounds

There are provided novel compounds of formula (I) wherein R, R, R, R, M, Q, T, U, Y, V and W are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain 

Substituted thiophene compounds

There are provided novel compounds of formula (I), wherein R, R, R, T, U, X, Y, V and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain 

Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase

There are provided novel compounds of formula (I) wherein R, R, R, T, U, X, Y, V and W are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease, CNS disorders and pain.

Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase

There are provided novel compounds of formula (I), wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.

Phenylheteroalkylamine derivatives

There is disclosed the use of a compound of formula (I) wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.

Use of phenylheteroakylamine derivatives

There are provided novel compounds of formula (I), wherein R , R , X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.

Growing community of inventors

Loughborough, United Kingdom

Antonio Mete